TITLE

ALLIANCE PLANS EUROPEAN PHASE 3 STUDY FOR OXYGENT

PUB. DATE
May 2002
SOURCE
Worldwide Biotech;May2002, Vol. 14 Issue 5, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the announcement of Alliance Pharmaceutical Corp. that representatives from Alliance and Baxter Healthcare Corp. have met with selected European regulatory authorities to review the clinical development plans for the intravascular oxygen carrier Oxygent.
ACCESSION #
6589532

 

Related Articles

  • Big lift for biomeds; FDA gives Alliance drug OK. Fikes, Bradley J. // San Diego Business Journal;8/23/93, Vol. 14 Issue 34, p5 

    Reports on the Food and Drug Administration's approval of a diagnostic drug produced by Alliance Pharmaceutical Corp. Imagent GI, a contrast agent for magnetic resonance imaging pictures of the bowel; Sales estimates; Market for temporary blood substitutes and cell oxygenator; Effect on San...

  • Alliance Pharmaceutical Corp.  // San Diego Business Journal;11/1/93, Vol. 14 Issue 44, Business action p1A 

    Introduces Alliance Pharmaceutical Corp.'s products based on perfluorochemicals. Temporary red blood cell substitute called Oxygent; `Liquid breathing' drug called LiquiVent; Oral contrast agent called Imagent GI; More.

  • OXYGENT REDUCES NEED FOR DONOR BLOOD IN PHASE 3 STUDY.  // Biotech Business;Oct2000, Vol. 13 Issue 10, p4 

    Reveals the results of a study citing that Oxygent from Alliance Pharmaceutical Corp. was found to significantly reduce the need for donor blood in patients undergoing surgical procedures.

  • Mixing medicines at Alliance. Hasenfuss, Marc // Finance Week;10/25/2002, p28 

    Analyzes the business performance of South African drug firm Alliance Pharmaceuticals, a subsidiary of Forim Holdings. Continued decline of Alliance under the leadership of chief executive Meyer Gelbart; Possible growth of Alliance with a stronger involvement from shareholders Thebe Healthcare...

  • A dose of good medicine. Hasenfuss, Marc // Finance Week;6/9/2003, p29 

    Looks at the prospects for South Africa-based Alliance Pharmaceutical Corp. for the second half of 2003. Emergence of a consortium led by Thebe and healthcare expert Ian Black; Shareholders' contention that management consistently underperformed its performance mandate; Trading margins; Cash...

  • Alliance Stock Dips Slightly After Rival Drug Approval. Webb, Marion // San Diego Business Journal;4/16/2001, Vol. 22 Issue 16, p6 

    Reports the stock decline of Alliance Pharmaceutical Corp. in San Diego, California. Percentage of stock of the rival drugmaker Biopure Inc.; Plan of the company to file for regulatory approval; Benefits of the partnership between Alliance and Baxter International Inc.

  • A sugar-coated pill. Hasenfuss, Marc // Finance Week;12/2/2002, p35 

    Reports the much improved set of interim results for jittery shareholders in the Alliance Pharmaceuticals in South Africa. Company operations of the Alliance; Increase rate of the after-tax profit; Calculation of the cash flow of the company.

  • Artificial Blood Tests Good Sign for European Approvals. Webb, Marion // San Diego Business Journal;09/18/2000, Vol. 21 Issue 38, p10 

    Reports on developments related to biotechnology industries in San Diego, California as of May 26, 2000. Alliance Pharmaceutical Corp.'s announcement of the results from a large-stage trial of its artificial blood substitute Oxygent; Losses incurred by Illumina Inc. for the second quarter...

  • IN THE PIPELINE.  // Drug Utilization Review;Feb2001, Vol. 17 Issue 2, p16 

    Presents updates on clinical trials in the United States (U.S.). Details on the clinical trials initiated by AeroGen Inc. for its insulin inhaler; Completion of Alliance Pharmaceutical Corporation's clinical trial on its intrapulmonary agent perflubron; Result of the clinical trial conducted by...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics